The successful execution of a biomarker strategy requires a flexible approach. Medpace offers an extensive menu of biomarkers that use state of the art techniques and provide results that enable patient stratification and improve prediction of drug efficacy and safety. Biomarkers are validated in GLP / GCP / CLIA environments depending on use of biomarkers and requirements of the clinical trial.
Medpace’s central laboratory biomarker team is led by PhD level scientists who oversee the robust pipeline of new biomarker validations. The central lab validates all assays based on guidelines from the Clinical and Laboratory Standards Institute (CLSI) and in accordance with CAP and CLIA regulations. Medpace central laboratories validate new biomarkers quickly in an industry-leading 10 – 12 weeks.
Medpace’s central lab and bioanalytical lab expertise in biomarker development and validation are enhanced by the experience and capabilities of our network of reference and strategic laboratory partners as a seamless service to our clients.
Important Cookie Information – This message will only appear once.
Medpace websites use cookies. By continuing to browse the site you are agreeing to our use of cookies.
For more details about cookies and their use, please see our Privacy Policy.
